Please use this identifier to cite or link to this item:
Title: Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.
Austin Authors: Aldape, Kenneth;Amin, Samirkumar B;Ashley, David M;Barnholtz-Sloan, Jill S;Bates, Amanda J;Beroukhim, Rameen;Bock, Christoph;Brat, Daniel J;Claus, Elizabeth B;Costello, Joseph F;de Groot, John F;Finocchiaro, Gaetano;French, Pim J;Gan, Hui K ;Griffith, Brent;Herold-Mende, Christel C;Horbinski, Craig;Iavarone, Antonio;Kalkanis, Steven N;Karabatsou, Konstantina;Kim, Hoon;Kouwenhoven, Mathilde C M;McDonald, Kerrie L;Miletic, Hrvoje;Nam, Do-Hyun;Ng, Ho Keung;Niclou, Simone P;Noushmehr, Houtan;Ormond, Ryan;Poisson, Laila M;Reifenberger, Guido;Roncaroli, Federico;Sa, Jason K;Sillevis Smitt, Peter A E;Smits, Marion;Souza, Camila F;Tabatabai, Ghazaleh;Van Meir, Erwin G;Verhaak, Roel G W;Watts, Colin;Wesseling, Pieter;Woehrer, Adelheid;Yung, W K Alfred;Jungk, Christine;Hau, Ann-Christin;van Dyck, Eric;Westerman, Bart A;Yin, Julia;Abiola, Olajide;Zeps, Nikolaj;Grimmond, Sean;Buckland, Michael;Khasraw, Mustafa;Sulman, Erik P;Muscat, Andrea M;Stead, Lucy
Affiliation: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA
Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, USA
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
National Brain Tumor Society, Newton, MA, USA
Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Yale School of Public Health, New Haven, CT, and Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA
University of California San Francisco, San Francisco, CA, USA
University of Texas, MD, and Anderson Cancer Center, Houston, TX, USA
Fondazione IRCCS Istituto Neurologico Besta, Milano, Italy
Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Radiology, Henry Ford Health System, Detroit, MI, USA
Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
Department of Neurology, Department of Pathology, Institute for Cancer Genetics, Columbia University Medical Center, New York, USA
Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA
Salford Royal Hospital, Stott Lane, Greater Manchester, UK
Department of Neurology, VU University Medical Center/Brain Tumor Center, Amsterdam, The Netherlands
Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Sydney, Australia
Department of Pathology, Haukeland University Hospital, Bergen, Norway
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Department of Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
Luxembourg Institute of Health, NorLux Neuro-Oncology Laboratory, Luxembourg
Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA
Department of Neuropathology, Heinrich Heine University Duesseldorf Medical Faculty, Duesseldorf, Germany
Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, UK
Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, University Hospital, Tübingen, Germany
Departments of Neurosurgery, Hematology, and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, GA, USA
Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, UK
Department of Pathology, VU University Medical Center/Brain Tumor Center Amsterdam, Amsterdam, The Netherlands
Institute of Neurology, Medical University of Vienna, Vienna, Austria
Anderson Cancer Center, Houston, TX, USA
Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
Brain Tumor Center Amsterdam, Cancer Center Amsterdam, VU Medical Center, Amsterdam, The Netherlands
Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Australia
Monash University and Epworth Health, Melbourne, Victoria, Australia
University of Melbourne and Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia
Royal Prince Alfred Hospital and University of Sydney, NSW, Australia
University of Sydney, NSW, Australia
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Deakin University, Geelong, Victoria, Australia
St James's University Hospital, Leeds, UK
Princess Máxima Center for Pediatric Oncology and University Medical Center Utrecht, The Netherlands
Issue Date: 8-Feb-2018 2018-02-08
Publication information: Neuro-oncology 2018; online first: 8 February
Abstract: Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas (TCGA) and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal AnalySiS Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities, and ultimately, improved outcomes for a patient population in need.
DOI: 10.1093/neuonc/noy020
PubMed URL: 29432615
Type: Journal Article
Subjects: characterization
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 8, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.